feedback

Course Director

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP

Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Accredited by

Penn State College of Medicine / Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CE
Credit Amount:1.0 Credits
Release Date:2017-Aug-24
Expiration Date:2018-Aug-23
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, a hematologic oncology expert takes you on a tour of key data and clinical considerations in the modern management of patients with multiple myeloma. Topics covered include the most recent developments on novel agent classes and next-generation therapeutics for myeloma, as well as perspectives on individualizing care in both newly-diagnosed and relapsed/refractory disease—how do age, eligibility for stem-cell transplantation, high-risk features or comorbid illnesses, or need for maintenance therapy affect treatment selection? Best practices for managing treatment-related adverse events in patients with myeloma receiving novel therapies are also reviewed.

Upon completion of this activity, participants will be able to:

  • Discuss updated clinical data on the treatment role, efficacy, and safety of novel agent classes and next-generation therapeutics in myeloma, including proteasome inhibitors, immunomodulatory drugs, immunotherapies, and epigenetic agents, among others
  • Recommend individualized treatment regimens in newly-diagnosed myeloma, including for elderly patients, individuals eligible or ineligible for stem-cell transplantation, and those requiring continuous/maintenance therapy
  • Select individualized regimens for patients with relapsed/refractory myeloma, including individuals with early relapse or treatment-refractory disease
  • Manage treatment-related adverse events in patients with myeloma, including those receiving regimens that contain novel components

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, advanced practice nurses, and other clinicians involved in the care of patients with multiple myeloma.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: August 24, 2017 - August 23, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Penn State College of Medicine and Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Course Director

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen, Inc.; Bristol-Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Millennium (Takeda Oncology); Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals Inc.
Grant/Research Support from Bristol-Myers Squibb; Celgene Corporation; and Takeda Pharmaceuticals U.S.A., Inc.

Sagar Lonial, MD, FACP, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: next-generation agents such as proteasome inhibitors, IMiDs, antibodies, and other innovative therapeutics.

Nurse Reviewer

Pamela Ash, RN, MSN, CBCN
Supportive Care Nurse Clinician
Mary Babb Randolph Cancer Center Clinic
West Virginia University
Morgantown, West Virginia

Pamela Ash, RN, MSN, CBCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

The associates of Medical Learning Institute, Inc. do not have any financial relationships or relationships to products or devices with any commercial interest.

Disclaimer

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6171-18-T.

Nurses

Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour(s).

Providership

This CME/CE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; this activity is also co-provided by Medical Learning Institute, Inc.

Support

This activity is supported by educational grants from Celgene Corporation, Merck & Co., Inc., and Takeda Oncology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.